TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

105.70
+0.09 (0.09%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
356 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 14 opinions in the last 12 months.

Abbott Labs has faced significant challenges over the past year, with a drop of around 30% in stock value and lowered growth guidance leading to a struggle in maintaining investor confidence. Many experts acknowledge the company's high-quality status within the healthcare sector, emphasizing the potential long-term growth, especially following its recent acquisition aimed at enhancing cancer treatment capabilities. While some analysts are cautious due to current market conditions and recent performance, others remain optimistic about Abbott's diversified business model and reliable dividend, indicating that organic growth in various segments remains robust. Despite recent setbacks and technical weaknesses, there are signs that the company might be turning a corner, positioning it for future recovery. Overall, views on Abbott are mixed, with a blend of caution and praise for its overall quality.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Bristol-Meyers, BMY
PAST TOP PICK

Abbott Labs(ABT)

Jun 16, 2021
(A Top Pick Jun 24/20, Up 29%) Recently revised guidance by 10-15% of earnings, as they saw a sharp decline in Covid testing. Still growing earnings in double digits. Medical devices and diagnostics are still doing well. Dividend is not high, but increased consistently. She's buying for new clients on this pullback.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$110.58

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Jun 15, 2021

Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.

Photo of Gordon ReidGordon Reid
No
Unlock Rating
$110.66

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jun 08, 2021
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
Photo of Chris BlumasChris Blumas
Owned
Unlock Rating
$108.10

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Jun 04, 2021
It is trading at around 34x earnings. It hasn't done much in the last year. It is where it was last year, maybe 10% up. Compared to the rest of the market, it hasn't moved. Big pharma was out of favour a couple years ago. This has now come back into favour. It is fully valued now. Has had a wonderful run. A little expensive.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$109.35

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Abbott Labs(ABT)

Jun 03, 2021
(A Top Pick Oct 08/20, Up 0.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $109. To remain disciplined, we recommend covering the balance of the holding. Combined with the previous recommendation to cover 50% of the position, this will result in a net investment gain of 9%.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$109.00

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 20, 2021

ABT vs. MRK Both are great companies. ABT is the leading supplier of products to the medical industry. Merck has incredible products as a global pharmaceutical company. You could hold either.

Photo of Bruce MurrayBruce MurrayUnlock Rating
$117.66

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 19, 2021

ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

Photo of Stan WongStan WongUnlock Rating
$116.21

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 18, 2021
A diversified US healthcare company in diagnostics, branded pharmaceuticals, nutrition and medical devices. It produces a lot of Covid-testing kits, which has boosted their bottom line. They can maintain double-digit earnings growth based on growth in medical devices. For instance, a diagnostic kit for diabetes (don't need to prick finger) is popular. About 40% of products are sold in emerging markets. They increase their dividend annually, for the past 49 years. Pays a 1.5% dividend. This has pulled back, so buy now. (Analysts’ price target is $133.26)
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$117.63

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 16, 2021
They report Tuesday. They've done great work with their Covid test that they will likely hit it out of the park.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$124.35

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 14, 2021

Liked BSX better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Volumes in medical devices are not recovering as he expected. He owns ABT instead, a diversified player with a very strong balance sheet.

Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$121.68

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Mar 01, 2021
It has done quite well compared to other healthcare stocks. They have had a lot of regulatory approvals and had strong earnings in Q2-20. In May the sector can do quite well, seasonally. Given its success across its divisions, he would say it is a good stock to hold even before its seasonal period.
Photo of Brooke ThackrayBrooke ThackrayUnlock Rating
$122.68

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Feb 24, 2021
This can still go higher. No need to worry about their diabetes franchise.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$122.38

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Abbott Labs(ABT)

Feb 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)Unlock Rating
$125.95

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Feb 11, 2021
Diversified medical device company. Acquisitions increased leverage, but they've paid it down. Less focused on slower growth business, more on devices. Great quality. Positive results from Covid testing have exceeded estimates.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$126.39

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jan 22, 2021
They report Wednesday. They need to mass-produce their quick Covid test that the FDA approved. That said, he expects a beat from them because of progress in Abbott's blood-sugar monitor.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$112.84

Stock price when the opinion was issued

$105.70

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 76 to 90 of 222 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like